Empowered Funds LLC Invests $1.03 Million in DaVita Inc. $DVA

Empowered Funds LLC bought a new stake in DaVita Inc. (NYSE:DVA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,641 shares of the company’s stock, valued at approximately $1,033,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fifth Third Bancorp increased its stake in DaVita by 831.4% in the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock valued at $5,903,000 after acquiring an additional 34,287 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of DaVita by 30.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock worth $9,963,000 after purchasing an additional 10,477 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of DaVita by 27.4% in the 1st quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock worth $32,627,000 after purchasing an additional 45,609 shares in the last quarter. Invst LLC bought a new position in shares of DaVita during the 2nd quarter valued at about $1,238,000. Finally, LSV Asset Management raised its holdings in shares of DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after buying an additional 9,739 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $183.87 on Friday. The stock has a market cap of $11.73 billion, a P/E ratio of 15.05, a PEG ratio of 0.47 and a beta of 0.83. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The firm’s 50 day moving average price is $208.62 and its 200-day moving average price is $184.28.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on DVA shares. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and increased their price target for the company from $201.00 to $220.00 in a research report on Friday, August 7th. UBS Group boosted their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $221.75.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Waters sold 15,405 shares of DaVita stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.